Cristiano De Stefanis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/430270/publications.pdf

Version: 2024-02-01

26 papers 1,451 citations

567281 15 h-index 24 g-index

26 all docs

26 docs citations

26 times ranked 2877 citing authors

#	Article	IF	CITATIONS
1	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma $H3K27M$ -mutant. Neuro-Oncology, 2022, 24, $1150-1163$.	1.2	31
2	AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 2021, 592, 799-803.	27.8	78
3	Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. Obesity Surgery, 2021, , 1.	2.1	6
4	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. Journal of Experimental and Clinical Cancer Research, 2021, 40, 364.	8.6	15
5	The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. Journal of Pediatrics, 2020, 216, 117-127.e2.	1.8	14
6	\hat{l}^2 -Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	3.7	48
7	HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation. Liver International, 2020, 40, 3127-3139.	3.9	8
8	Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5795.	4.1	12
9	IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2020, 22, iii362-iii362.	1.2	O
10	The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. International Journal of Molecular Sciences, 2019, 20, 3460.	4.1	16
11	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. Neuro-Oncology, 2019, 21, ii123-ii124.	1.2	0
12	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with <scp>NAFLD</scp> . Liver International, 2018, 38, 342-349.	3.9	37
13	Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. PLoS ONE, 2018, 13, e0201566.	2.5	6
14	The exposure to uteroplacental insufficiency is associated with activation of unfolded protein response in postnatal life. PLoS ONE, 2018, 13, e0198490.	2.5	18
15	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaâ€omicsâ€based approach. Hepatology, 2017, 65, 451-464.	7.3	572
16	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Cell Death and Differentiation, 2017, 24, 889-902.	11.2	53
17	The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. Journal of Pediatrics, 2017, 180, 31-37.e2.	1.8	95
18	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. PLoS ONE, 2016, 11, e0157246.	2.5	50

#	Article	IF	CITATION
19	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE, 2016, 11, e0168216.	2.5	83
20	LPS-induced TNF- \hat{l} ± factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget, 2015, 6, 41434-41452.	1.8	100
21	Arginase 1: A potential marker of a common pattern of liver steatosis in HCV and NAFLD children. Journal of Hepatology, 2015, 62, 1207-1208.	3.7	6
22	Altered gut–liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax, 2015, 70, 769-781.	5.6	47
23	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics, 2014, 14, 763-771.	3.1	22
24	EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD. International Journal of Molecular Sciences, 2013, 14, 24154-24168.	4.1	44
25	Retinoids counteract insulin resistance and liver steatosis: What's the potential mechanism?. Hepatology, 2013, 58, 1185-1185.	7.3	1
26	Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e67160.	2.5	89